More on NTLA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $11.16 |
|
|||
| Open | $11.00 | ||||
| 52 Wk High | $30.40 | ||||
| 52 Wk Low | $11.86 | ||||
| Day High | $11.24 | ||||
| Day Low | $10.58 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 3,564,678 | ||||
- Intellia Therapeutics names new chief medical officer
- Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
- Form 4 Intellia Therapeutics, For: Oct 02 Filed by: Dube Michael P
- Barclays Starts Intellia Therapeutics (NTLA) at Underweight
- Form 144 Intellia Therapeutics, Filed by: Clark Eliana
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)
- Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens
- FDA accepts Intellia's lonvo-z application with priority review status
- Intellia Therapeutics (NTLA) Reiterated at Market Outperform by Citizens on HAE Opportunity
Entities mentioned with NTLA
- Twitter | View Related Stories »
- ARK | View Related Stories »
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- Show More...
